|
1
|
Passarello K, Kurian S and Villanueva V:
Endometrial cancer: An overview of pathophysiology, management, and
care. Semin Oncol Nurs. 35:157–165. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Banz-Jansen C, Helweg LP and Kaltschmidt
B: Endometrial cancer stem cells: Where do we stand and where
should we go? Int J Mol Sci. 23:34122022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McAlpine JN, Temkin SM and Mackay HJ:
Endometrial cancer: Not your grandmother's cancer. Cancer.
122:2787–2798. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Emons G and Vordermark D: Adjuvant
treatment for endometrial cancer. Curr Opin Oncol. 31:404–410.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de Boer SM, Powell ME, Mileshkin L,
Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA,
Khaw P, D'Amico R, et al: Adjuvant chemoradiotherapy versus
radiotherapy alone in women with high-risk endometrial cancer
(PORTEC-3): Patterns of recurrence and post-hoc survival analysis
of a randomised phase 3 trial. Lancet Oncol. 20:1273–1285. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Han Y, Jin SW, Lee GH, Choi JH, Lee HS,
Chung YC, Jeong HG and Lee KY: Stimulatory effects of platycodin D
on osteoblast differentiation. J Cell Biochem. 120:13085–13094.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kong Y, Lu ZL, Wang JJ, Zhou R, Guo J, Liu
J, Sun HL, Wang H, Song W, Yang J and Xu HX: Platycodin D, a
metabolite of platycodin grandiflorum, inhibits highly metastatic
MDA-MB-231 breast cancer growth in vitro and in vivo by targeting
the MDM2 oncogene. Oncol Rep. 36:1447–1456. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chun J and Kim YS: Platycodin D inhibits
migration, invasion, and growth of MDA-MB-231 human breast cancer
cells via suppression of EGFR-mediated Akt and MAPK pathways. Chem
Biol Interact. 205:212–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou R, Lu Z, Liu K, Guo J, Liu J, Zhou Y,
Yang J, Mi M and Xu H: Platycodin D induces tumor growth arrest by
activating FOXO3a expression in prostate cancer in vitro and in
vivo. Curr Cancer Drug Targets. 14:860–871. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang W, Guo X and Dan H: α2A-adrenergic
receptor inhibits the progression of cervical cancer through
blocking PI3K/AKT/mTOR pathway. Onco Targets Ther. 13:10535–10546.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
StarBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daina A, Michielin O and Zoete V:
SwissTargetPrediction: Updated data and new features for efficient
prediction of protein targets of small molecules. Nucleic Acids
Res. 47:W357–W364. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu KH and Broaddus RR: Endometrial cancer.
N Engl J Med. 383:2053–2064. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Post CCB, Westermann AM, Bosse T,
Creutzberg CL and Kroep JR: PARP and PD-1/PD-L1 checkpoint
inhibition in recurrent or metastatic endometrial cancer. Crit Rev
Oncol Hematol. 152:1029732020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brooks RA, Fleming GF, Lastra RR, Lee NK,
Moroney JW, Son CH, Tatebe K and Veneris JL: Current
recommendations and recent progress in endometrial cancer. CA
Cancer J Clin. 69:258–279. 2019.PubMed/NCBI
|
|
17
|
Chen D, Chen T, Guo Y, Wang C, Dong L and
Lu C: Platycodin D (PD) regulates LncRNA-XIST/miR-335 axis to slow
down bladder cancer progression in vitro and in vivo. Exp Cell Res.
396:1122812020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang MY, Jiang XM, Xu YL, Yuan LW, Chen
YC, Cui G, Huang RY, Liu B, Wang Y, Chen X and Lu JJ: Platycodin D
triggers the extracellular release of programed death Ligand-1 in
lung cancer cells. Food Chem Toxicol. 131:1105372019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peng Y, Fan JY, Xiong J, Lou Y and Zhu Y:
MiR-34a enhances the susceptibility of gastric cancer to platycodin
d by targeting survivin. Pathobiology. 86:296–305. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Khan M, Maryam A, Zhang H, Mehmood T and
Ma T: Killing cancer with platycodin D through multiple mechanisms.
J Cell Mol Med. 20:389–402. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Zhai T, Hei Z, Zhou D, Jin L, Han
C and Wang J: Effects of platycodin D on apoptosis, migration,
invasion and cell cycle arrest of gallbladder cancer cells. Oncol
Lett. 20:3112020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li T, Xu XH, Tang ZH, Wang YF, Leung CH,
Ma DL, Chen XP, Wang YT, Chen Y and Lu JJ: Platycodin D induces
apoptosis and triggers ERK- and JNK-mediated autophagy in human
hepatocellular carcinoma BEL-7402 cells. Acta Pharmacol Sin.
36:1503–1513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu D, Zhang W, Chen Y, Ma H and Wang M:
Platycodin D inhibits proliferation, migration and induces
chemosensitization through inactivation of the NF-κB and
JAK2/STAT3 pathways in multiple myeloma cells. Clin Exp Pharmacol
Physiol. 46:1194–1200. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Z, Zhao M, Zheng W and Liu Y:
Platycodin D, a triterpenoid saponin from Platycodon grandiflorum,
suppresses the growth and invasion of human oral squamous cell
carcinoma cells via the NF-κB pathway. J Biochem Mol
Toxicol. 31:219342017. View Article : Google Scholar
|
|
25
|
Sivalingam VN, Latif A, Kitson S, McVey R,
Finegan KG, Marshall K, Lisanti MP, Sotgia F, Stratford IJ and
Crosbie EJ: Hypoxia and hyperglycaemia determine why some
endometrial tumours fail to respond to metformin. Br J Cancer.
122:62–71. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin YC, Lin YC, Kuo WW, Shen CY, Cheng YC,
Lin YM, Chang RL, Padma VV and Huang CY and Huang CY: Platycodin D
reverses pathological cardiac hypertrophy and fibrosis in
spontaneously hypertensive rats. Am J Chin Med. 46:537–549. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Urbinati G, Ali HM, Rousseau Q, Chapuis H,
Desmaele D, Couvreur P and Massaad-Massade L: Antineoplastic
effects of siRNA against TMPRSS2-ERG junction oncogene in prostate
cancer. PLoS One. 10:e01252772015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rivero EM, Martinez LM, Bruque CD,
Gargiulo L, Bruzzone A and Luthy IA: Prognostic significance of α-
and β2-adrenoceptor gene expression in breast cancer patients. Br J
Clin Pharmacol. 85:2143–2154. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu C, Sun G, Yuan G, Wang R and Sun X:
Effects of platycodin D on proliferation, apoptosis and PI3K/Akt
signal pathway of human glioma U251 cells. Molecules.
19:21411–21423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Uko NE, Guner OF, Matesic DF and Bowen JP:
Akt pathway inhibitors. Curr Top Med Chem. 20:883–900. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng H and Liu JF: Studies on the
relationship between P13K/AKT signal pathway-mediated MMP-9 gene
and lung cancer. Eur Rev Med Pharmacol Sci. 21:753–759.
2017.PubMed/NCBI
|
|
32
|
Pompura SL and Dominguez-Villar M: The
PI3K/AKT signaling pathway in regulatory T-cell development,
stability, and function. J Leukoc Biol.
22:10.1002/JLB.2MIR0817–349R. 2018.
|
|
33
|
Chen ZF, Wang J, Yu Y and Wei W:
MicroRNA-936 promotes proliferation and invasion of gastric cancer
cells by down-regulating FGF2 expression and activating P13K/Akt
signaling pathway. Eur Rev Med Pharmacol Sci. 24:6707–6715.
2020.PubMed/NCBI
|
|
34
|
Xu J, Li Z, Su Q, Zhao J and Ma J: TRIM29
promotes progression of thyroid carcinoma via activating P13K/AKT
signaling pathway. Oncol Rep. 37:1555–1564. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fan Y, Dong Z, Shi Y, Sun S, Wei B and
Zhan L: NLRC5 promotes cell migration and invasion by activating
the PI3K/AKT signaling pathway in endometrial cancer. J Int Med
Res. 48:3000605209253522020. View Article : Google Scholar : PubMed/NCBI
|
